FDA Approval Summary: Sonidegib-Response

Affiliations

¹ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. stacy.shord@fda.hhs.gov.
² Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

Comment

Stacy S Shord et al. Clin Cancer Res. 2017.

. 2017 Oct 1;23(19):5994.

doi: 10.1158/1078-0432.CCR-17-2135.

¹ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. stacy.shord@fda.hhs.gov.
² Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

No abstract available

Comment on

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.
Casey D, Demko S, Shord S, Zhao H, Chen H, He K, Putman A, Helms W, Keegan P, Pazdur R. Casey D, et al. Clin Cancer Res. 2017 May 15;23(10):2377-2381. doi: 10.1158/1078-0432.CCR-16-2051. Epub 2017 Jan 10. Clin Cancer Res. 2017. PMID: 28073840 Clinical Trial.
FDA Approval Summary: Sonidegib-Letter.
Gyawali B, Ando Y. Gyawali B, et al. Clin Cancer Res. 2017 Oct 1;23(19):5993. doi: 10.1158/1078-0432.CCR-17-1460. Clin Cancer Res. 2017. PMID: 28972085 No abstract available.